News

RIVANNA® Announces Partnership With BOMImed to Increase Distribution of Accuro® in Canada

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with BOMImed, a recognized manufacturer of anesthesia and critical care related consumables to represent and distribute the Accuro® portfolio of products in Canada.

BOMImed is a choice distribution partner for RIVANNA as its focus is within the fields of anesthesia and critical care, with company resources dedicated to providing the highest level of service inside of these markets.

Danielle Faulk, North America Director of Sales and Distribution at RIVANNA, commented, “This strategic partnership with BOMImed will efficiently enhance Accuro’s service offerings, attract new customers and expand coverage to a more expansive range of Canadian healthcare organizations. Our growing worldwide market adoption reflects Accuro’s value to its customers. It signifies a migration away from palpation-based needle placement in favor of a safer and more efficient image-guided standard for spinal needle placement.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™ AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

David Olivier, President and CEO of BOMImed, said, “The BOMImed team is excited to introduce Accuro’s trailblazing technology to an expanding market supporting spinal needle guidance procedures in Canada. Accuro technology and its demonstrated clinical benefits underpin our mission to stay ahead of the curve in the products we sell and enhance the lives within the anesthesia and critical care community.”

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by